Pfizer Inc (PFE)

PFE on New York Consolidated

29.89USD
15 Apr 2014
Price Change (% chg)

$0.02 (+0.07%)
Prev Close
$29.87
Open
$29.97
Day's High
$30.15
Day's Low
$29.60
Volume
30,079,681
Avg. Vol
28,563,497
52-wk High
$32.96
52-wk Low
$27.12

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.75
Market Cap (Mil.): $191,102.59
Shares Outstanding (Mil.): 6,393.53
Dividend: 0.26
Yield (%): 3.48

Financials

  PFE Industry Sector
P/E (TTM): 18.11 32.69 32.79
EPS (TTM): 1.65 -- --
ROI: 7.49 19.77 19.03
ROE: 14.45 20.48 19.80
Search Stocks

U.S. drug industry group defends price of Gilead hepatitis drug

WASHINGTON - The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

10 Apr 2014

U.S. drug industry group defends price of Gilead hepatitis drug

WASHINGTON, April 10 - The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

10 Apr 2014

Untaxed U.S. corporate profits held overseas top $2.1 trln -study

* Senate Finance Committee Chairman Wyden calls for reform

08 Apr 2014

US STOCKS-Wall Street falls on broad weakness, Pfizer drags

* Indexes down: Dow 0.77 pct, S&P 0.76 pct, Nasdaq 0.97 pct (Updates to midday)

07 Apr 2014

US STOCKS-Wall St flat as momentum stocks stabilize; Pfizer drags

* Dow down 0.17 pct, S&P down 0.08 pct, Nasdaq up 0.09 pct (Updates to open, adds quote)

07 Apr 2014

Pfizer drug doubles time to breast cancer tumor growth in trial

- Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.

06 Apr 2014

Pfizer drug doubles time to breast cancer tumor growth in trial

April 6 - Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.

06 Apr 2014

Apple, Pfizer, others form 'go slow' U.S. patent lobby group

WASHINGTON - Major U.S. companies including Ford, Apple and Pfizer have formed a lobbying group aimed at pushing back at some changes to the patent system members of Congress have proposed, saying these measures would hinder protection of valuable inventions.

03 Apr 2014

Apple, Pfizer, others form "go slow" U.S. patent lobby group

WASHINGTON, April 3 - Major U.S. companies including Ford, Apple and Pfizer have formed a lobbying group aimed at pushing back at some changes to the patent system members of Congress have proposed, saying these measures would hinder protection of valuable inventions.

03 Apr 2014

BRIEF-IntegraGen jumps 10 pct on collaboration deal with Pfizer

PARIS, April 3 - Integragen SA : * Shares rise 10 percent on collaboration agreement with Pfizer * Agreement with Pfizer to evaluate Integragen's proprietary hepatocellular carcinoma molecular signature

03 Apr 2014

Competitors

  Price Change
The Procter & Gamble Company (PG.N) $80.84 +0.03
Johnson & Johnson (JNJ.N) $99.20 +2.06
Novartis AG (NOVN.VX) CHF74.50 +0.95
Merck & Co., Inc. (MRK.N) $56.05 +0.48
Roche Holding Ltd. (ROG.VX) CHF254.90 +1.60
Abbott Laboratories (ABT.N) $37.97 +0.23
Bayer AG (BAYGn.DE) €92.25 +0.74
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.00 +0.98
AstraZeneca plc (AZN.L) 3,760.00p +37.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$115.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks